Abstracted Scientific Content

Escalating prices of generic drugs targeted by US anti-gouging legislation

Published in: Volume 8 / Year 2019 / Issue 2
Author(s):
Page: 88

Submitted: 29 January 2019; Revised: 4 February 2019; Accepted: 5 February 2019; Published online first: 14 February 2019 Generic prescription drug prices have been escalating rapidly in the US. In… Read More »

Regulatory requirements for the acceptance of foreign comparator products in the participants of the International Generic Drug Regulators Programme

Published in: Volume 8 / Year 2019 / Issue 1
Page: 42-4

Submitted: 4 March 2019; Revised: 25 April 2019; Accepted: 27 April 2019; Published online first: 30 April 2019 The availability of quality generic drug products plays an increasingly important role… Read More »

US generic prescription drug markets 2004‒2016

Published in: Volume 7 / Year 2018 / Issue 4
Author(s):
Page: 164

Submitted: 6 December 2018; Revised: 12 December 2018; Accepted: 14 December 2018; Published online first: 19 December 2018 Generic drugs are currently central to disease treatment in the US. However,… Read More »

How does generic drug policy affect market prices?

Published in: Volume 7 / Year 2018 / Issue 3
Author(s):
Page: 136

Submitted: 21 November 2018; Revised: 22 November 2018; Accepted: 28 November 2018; Published online first: 4 December 2018 A study published by the World Health Organization (WHO) compares the effect… Read More »

EU risk-sharing agreements between 2000−2015

Published in: Volume 7 / Year 2018 / Issue 3
Author(s):
Page: 134-5

Submitted: 20 June 2018; Revised: 14 August 2018; Accepted: 18 August 2018; Published online first: 31 August 2018 The ageing population, longer life expectancies, and the increasing cost of drugs… Read More »

A call for coherence in EU legislation to promote generics

Published in: Volume 7 / Year 2018 / Issue 2
Author(s):
Page: 92

Submitted: 6 May 2018; Revised: 7 May 2018; Accepted: 8 May 2018; Published online first: 18 May 2018 Data and market exclusivity for originator medicines in the European Union (EU)… Read More »

Barriers to generics policy reform: a US case study

Published in: Volume 7 / Year 2018 / Issue 1
Author(s):
Page: 48

Submitted: 29 December 2017; Revised: 5 January 2018; Accepted: 12 January 2018; Published online first: 19 January 2018 A recent comparison of generic drug markets [1] explores the history of… Read More »

A comparison of European and US generic drug markets

Published in: Volume 6 / Year 2017 / Issue 4
Author(s):
Page: 190-2

Submitted: 19 June 2017; Revised: 5 September 2017; Accepted: 6 September 2017; Published online first: 19 September 2017 Introduction Comparative research on the European and US generic drug markets based… Read More »

Randomized non-inferiority trial fails to find inferiority switching from infliximab originator to CT-P13 biosimilar

Published in: Volume 6 / Year 2017 / Issue 4
Author(s):
Page: 188-9

Submitted: 17 November 2017; Revised: 20 November 2017; Accepted: 22 November 2017; Published online first: 5 December 2017 The tumour necrosis factor (TNF) inhibitor infliximab is known to significantly improve… Read More »

‘To prescribe generics is to play with the life of the patient’: misconceptions of generics in Guatemala

Published in: Volume 6 / Year 2017 / Issue 3
Author(s):
Page: 147-8

Submitted: 13 September 2017; Revised: 17 September 2017; Accepted: 18 September 2017; Published online first: 25 September 2017 Both pharmacists and doctors in Guatemala lack trust in generic medicines, according… Read More »

Page 1 of 3 1 2 3 Next »
Go Back Print